The Role of Alpha2-Adrenergic Agonists in Attention-Deficit/Hyperactivity Disorder
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Psychostimulants are first-line therapy for patients with attention-deficit/hyperactivity disorder (ADHD). However, some patients are not optimal responders to monotherapy or present as comorbid for a variety of other disorders that either preclude the use of stimulants or produce a symptom complex that is resistant to monotherapy. Unfortunately, there are few agents well studied in combination with psychostimulants for patients with ADHD. The combination of psychostimulants with alpha2-adrenergic agonists may offer a complementary approach to treating such complex patients. The rationale for combination therapy is that the primary effects of stimulants and alpha2-adrenergic agonists are mediated by different but complementary mechanisms of action, emphasizing different neurotransmitter systems, which together modulate prefrontal cortex functioning. Although immediate-release clonidine and guanfacine have long been studied in ADHD, their usage has been limited by rapid absorption and clearance, negative side effects, and reduced efficacy compared with stimulants. New controlled-release formulations of the alpha2-adrenergic agonists have overcome some of these limitations, with recent clinical trials demonstrating their enhanced tolerability and effectiveness for treatment of ADHD in children and adolescents. Studies with each of these new formulations (ie, guanfacine extended release and clonidine hydrochloride extended-release tablets) in combination with psychostimulants have demonstrated that the addition of an alpha2-adrenergic agonist to psychostimulant therapy significantly enhances efficacy without compromising safety. This review will encompass the clinical study database for novel formulations of alpha2-adrenergic agonists, enabling the reader to appreciate their place in ADHD treatment as well as the potential utility of a combination approach with psychostimulants for patients with complex ADHD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory
Vijayraghavan, S., Wang, M., Birnbaum, S. G., Williams, G. V., & Arnsten, A. F. T. (2007) · Nature Neuroscience · doi:10.1038/nn1846 · Cited by 1,013
Wang, M., Ramos, B. P., Paspalas, C. D., Shu, Y., Simen, A., Duque, A., Vijayraghavan, S., Brennan, A., Dudley, A., Nou, E., et al. (2007) · Cell · doi:10.1016/j.cell.2007.03.015 · Cited by 672
Aron, A. R., & Poldrack, R. A. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.026 · Cited by 602
Tripp, G., & Wickens, J. R. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.07.026 · Cited by 492
Arnsten, A. F. T. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830050084013 · Cited by 458
Sallee, F. R., Mcgough, J., Wigal, T., Donahue, J., Lyne, A., & Biederman, J. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318191769e · Cited by 391
Self-citationArnsten, A. F. T. (2009) · CNS Drugs · doi:10.2165/00023210-200923000-00005 · Cited by 371
Arnsten, A. F., & Dudley, A. G. (2005) · Behavioral and Brain Functions · doi:10.1186/1744-9081-1-2 · Cited by 363
Biederman, J., Melmed, R. D., Patel, A., McBurnett, K., Konow, J., Lyne, A., Scherer, N., & for the SPD503 Study Group (2008) · Pediatrics · doi:10.1542/peds.2006-3695 · Cited by 317 · cited 1×
“R SIV to ta l s co re , m ea n ch an ge fr om b as el in e −15 −20 −25 Biederman et al, 2008 Sallee et al, 2009 Figure 2.”
Cited by
Millan, M. J., Agid, Y., Brüne, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., Connor, R., Davis, S., Deakin, B., DeRubeis, R. J., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3628 · Cited by 1,292
Clonidine Extended-Release: In Attention-Deficit Hyperactivity Disorder
Croxtall, J. D. (2011) · Pediatric Drugs · doi:10.2165/11208100-000000000-00000 · Cited by 190
Metabolic, toxicological, and safety considerations for drugs used to treat ADHD
Duong, S., Chung, K., & Wigal, S. B. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.671295 · Cited by 42
Guanfacine extended-release for cannabis use disorder: A pilot feasibility trial
Dakwar, E., Mahony, A., Choi, C. J., Pavlicova, M., Brooks, D., Mariani, J. J., & Levin, F. R. (2020) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2019.1620259 · Cited by 5
“Guanfacine, a selective α2A agonist currently FDAapproved for the treatment of ADHD and hypertension (11), can be dosed once daily and provides a more practical pharmacotherapy option than does lofexidine.”
BackgroundInfluential
Metadata
- Authors
- Sallee, F. R.
- Venue
- Postgraduate Medicine
- Publisher
- Informa UK Limited
- Published
- 2010-09-01
- Volume
- 122
- Issue
- 5
- Pages
- 78-87
- ISSN
- 0032-5481 (ISSN-L)
- 1941-9260
- OpenAlex
- W2323423445
- Cited by
- 37
- References
- 28
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Role of Alpha2-Adrenergic Agonists in Attention-Deficit/Hyperactivity Disorder. https://app.cochat.ai/papers/10.3810/pgm.2010.09.2204
- The paper
- Sallee, F. R. (2010). The Role of Alpha2-Adrenergic Agonists in Attention-Deficit/Hyperactivity Disorder. Postgraduate Medicine. https://doi.org/10.3810/pgm.2010.09.2204
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.